Study of aspirin on inhibiting the atherosclerotic plaque rupture and MMP-2 expression of abdominal aorta in atherosclerotic rabbits

Chinese Pharmacological Bulletin

Volumn 24, Issue 10, 2008, Pages 1335-1339

  Xue, Jie ^a   Hua, Yi Nan ^a   Gu, Zhen Lun ^a   Wu, Kai Yun ^a   Xie, Mei Lin ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Aspirin; Atherosclerotic plaque rupture; Cyclooxygenase 2; Macrophages; Matrix metalloproteinase 2

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; GELATINASE A; HISTAMINE; MESSENGER RNA; VIPER VENOM;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL AGGREGATION; CELL COUNT; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG MECHANISM; FOAM CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INHIBITION KINETICS; LIPID DIET; MACROPHAGE; MALE; MICROSCOPY; NONHUMAN; PROTEIN EXPRESSION; RABBIT; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 58149203428     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Xia X D, Lin W H. Current status in research of vulnerable atherosclerotic plaque[J]. Chin J Cardiovasc Med, 2005, 10 (2): 139-41.
2. Kuzuya M, Iguchi A. Role of matrix metalloproteinase in vascular remodeling[J]. J Atheroscler Thromb, 2003, 10 (5): 275-82.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients[J]. Br Med J, 2002, 324: 71-86.
4. Karna E, Palka J A. Inhibitory effect of acetylsalicylic acid on metalloproteinase activity in human lung adenocarcinoma at different stages of differentiation [J]. Eur J Pharmacol, 2002, 443: 1-6.
5. Mehta J L, Chen J, Yu F, et al. Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells [J]. Cardiovasc Res, 2004, 64: 243-9.
6. Cai B X, Xie M L, Gu Z L. Experimental study on rabbit atherosclerotic plaque rupture model [J]. Shanghai Lab Anim Sci, 2004, 24(4): 200-3.
7. Sano K, Kawasaki M, Ishihara Y, et al. Assessment of vulnerable plaques causing acute coronary syndrome using integrated backscatter intravascular ultrasound [J]. J Am Coll Cardiol, 2006, 47: 734-41.
8. Myoishi M, Hao H, Minarnino T, et al. Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome [J]. Circulation, 2007, 116: 1226-33.
9. Faxon D P, Cochair F V, Cochair L P, et al. Atherosclerotic vascular disease conference: writing group III: pathophysiology [J]. Circulation, 2004, 109 (21): 2617-25.
10. Molloy K J, Thompson M M, Jones J L, et al. Unstable carotid plaque exhibit raised matrix metalloproteinase-8 activity [J]. Circulation, 2004, 110(3): 337-43.
11. Libby P. Inflammation in atherosclerosis [J]. Nature, 2002, 420 (6917): 868-74.
12. Lutgens E, van Suylen R J, Faber B C, et al. Atherosclerotic plaque rupture:local or systemic process [J] ? Arterioscl Throm Vasc Biol, 2003, 23(12): 2123-30.
13. Wang T, Pu Y H, Yin J, et al. Vulnerable plaque and acute coronary syndrome [J]. Adv Cardiovasc Dis, 2007, 28 (2): 246-8.
14. Cipollone F, Fazia M, Lezzi A, et al. Balance between PGD Synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans[J]. Arterioscl Throm Vasc Biol, 2004, 24(7): 1259-65.
15. Gomez-Hernández A, Martín-Ventura J L, Sánchez-Galán E, et al. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-κB [J]. Atherosclerosis, 2006, 187: 139-49.
16. Hua Y N, Xue J, Zhu L J, et al. Influence of aspirin on blood lipid and platelet aggregation in atherosclerotic rabbits with hyperlipidemia [J]. Suzhou Univ J Med Sci, 2007, 27 (6): 16-9.
17. Wu W, Qi R M, Li R, et al. Aspirin inhibition of expression of inflammatory proteins induced by oxidized low-density lipoprotein in HUVECs [J]. Chin Pharmacol Bull, 2007, 23 (4): 472-5.